Evogene (EVGN) EBITDA Margin (2012 - 2026)
Evogene (EVGN) posted EBITDA Margin of 943.11% for Q1 2026, up 43.18% sequentially from 1659.87% in Q4 2025, and down 81392.0% YoY from N/an in Q1 2025.
Evogene (EVGN) EBITDA Margin (2012 - 2026) Analysis & Trends
Evogene has reported EBITDA Margin for 15 years, with the latest figure at 943.11% in Q1 2026.
- Quarterly EBITDA Margin fell 81392.0% year-over-year to 943.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 767.73% (down 49401.0% YoY) and the FY2025 annual result came in at 364.24%, down 2707.0% from the prior year.
- EBITDA Margin rose to 943.11% in Q1 2026 per EVGN's latest filing, from 1659.87% in the prior quarter.
- Over five years, EBITDA Margin peaked at 97.52% in Q1 2024 and troughed at 3398.73% in Q1 2022.
- A 5-year average of 1008.31% and a median of 873.08% in 2025 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 414326 bps in 2022, down 151915 bps in 2022.
- Over 5 years, EBITDA Margin stood at 573.03% in 2022, then tumbled by 130 bps to 1319.72% in 2023, then soared by 83 bps to 225.53% in 2024, then sank by 636 bps to 1659.87% in 2025, then jumped by 43 bps to 943.11% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 943.11%, 1659.87%, and 873.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -943.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -943.11% |
| Dec 31, 2025 | -1,659.87% |
| Sep 30, 2025 | -873.08% |
| Jun 30, 2025 | -347.40% |
| Mar 31, 2025 | -129.19% |
| Dec 31, 2024 | -225.53% |
| Sep 30, 2024 | -340.23% |
| Jun 30, 2024 | -765.12% |
| Mar 31, 2024 | -97.52% |
| Dec 31, 2023 | -1,319.72% |
| Sep 30, 2023 | -111.04% |
| Jun 30, 2023 | -1,208.10% |
| Mar 31, 2023 | -1,060.22% |
| Dec 31, 2022 | -573.03% |
| Sep 30, 2022 | -1,522.96% |
| Jun 30, 2022 | -2,566.35% |
| Mar 31, 2022 | -3,398.73% |
| Dec 31, 2021 | -2,794.86% |
| Sep 30, 2021 | -5,666.23% |
| Jun 30, 2021 | -5,515.56% |